Protocol Ledger

NCT06747949 · Phase III · RECRUITING

A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS)

Interventional Phase III clinical trial protocol NCT06747949 sponsored by Amgen in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-02-25 Enrollment: 844 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06747949
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)844 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06747949
Protocol FieldVerified Registry Value
NCT IdentifierNCT06747949
Consolidated Lead SponsorAmgen
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment844 participants (ESTIMATED)
Registered Start Date2025-02-25
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06747949
Hospital Research SiteLocationSite Profile
UC San Diego Health and Moores Cancer CenterSan Diego, CAOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Amgen across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI